Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | CA9 | Q16790 | 5/20 | 0.53 |
| ▸ | CA12 | O43570 | 4/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2466828 | 0.82 | CHRNA7 (0.66) | PTGS2PTGS1CHRNA7CA1CA2 | |
| SCHEMBL5309196 | 0.82 | CHRNA7 (0.66) | PTGS2PTGS1CHRNA7CA1CA2 | |
| SCHEMBL7210614 | 0.81 | PTGS2 (0.63) | PTGS2PTGS1CHRNA7CA1CA2 | |
| SCHEMBL7212037 | 0.81 | PTGS2 (0.63) | PTGS2PTGS1CHRNA7CA1CA2 | |
| SCHEMBL7216291 | 0.80 | PTGS2 (0.62) | PTGS2PTGS1CHRNA7CA1CA2 | |
| SCHEMBL1270876 | 0.80 | PTGS2 (0.62) | PTGS2PTGS1CHRNA7CA1CA2 | |
| SCHEMBL2462524 | 0.79 | PTGS2 (0.60) | PTGS2PTGS1CHRNA7CA1CA2 | |
| SCHEMBL7215890 | 0.79 | PTGS2 (0.60) | PTGS2PTGS1CHRNA7CA1CA2 | |
| SCHEMBL7216202 | 0.78 | PTGS2 (0.59) | PTGS2PTGS1CHRNA7CA1CA2 | |
| SCHEMBL10059496 | 0.78 | CA1 (0.61) | PTGS2PTGS1CHRNA7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20100216862-A1 | Pyrrole Derivatives As Therapeutic Compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7714022-B2 | Pyrrole derivatives as therapeutic compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| EP-2059238-A2 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | Myriad Genetics, Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| CN-101316817-A | Pyrrole derivatives as therapeutic compounds | MYRIAD GENETICS INC (US) | 2008-12-03 | — | — | CN | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| EP-1928827-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008031034-A2 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| EP-0799823-B1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | DAIICHI SANKYO CO LTD (JP) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007038684-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| US-RE39420-E1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-12-05 | — | — | US | disclosed |
| CN-1151126-C | 1, 2-diphenylpyrrole derivatives, their preparation and their therapeutic uses | ������������ʽ���� | 2004-05-26 | — | — | CN | disclosed |
| US-5908858-A | OSTEOPOROSIS; LEUKOTRIENE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1999-06-01 | — | — | US | disclosed |
| CN-1168372-A | 1, 2-diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 1997-12-24 | — | — | CN | disclosed |
| EP-0799823-A1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1997-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | NLN, SLC18A2, GOLT1B | PTGS2 2713/4885PTGS1 2459/4885CHRNA7 947/4885 |
| US-20100216862-A1 | Pyrrole Derivatives As Therapeutic Compounds | APP, PSEN2, PSEN1 | PTGS2 1374/4885PTGS1 1090/4885CHRNA7 2002/4885 |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | APP, PSEN2, PSEN1 | PTGS2 1374/4885PTGS1 1090/4885CHRNA7 2002/4885 |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | NLN, SLC18A2, GOLT1B | PTGS2 2713/4885PTGS1 2459/4885CHRNA7 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.